Jennifer Vaughn, MD, discusses how value-based care in hematology should consider cost and financial toxicity, as well as valuable patient experience.
Oral chemotherapy agents offer patients a reprieve from fees and facility costs, but they also put the cost of vital medications on the patient, highlighting an area of need, discusses Jennifer Vaughn, MD, assistant professor in the division of hematology at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.
Transcript
What strides are being made to improve and expand access to value-based care in hematology, and what more needs to be done?
Hematology, in itself, is a unique space in that we've had a lot of very rapid development and very effective, but also very expensive therapies, over the last couple of decades. I think some particular spaces that we really need to think about how we're going to create a value-based care experience for our patients are in the aggressive treatments of hematologic malignancies, with modalities such as stem cell transplant, CAR T therapies, gene therapy.
I sit in our classical hematology section within our division and work closely with hemophilia and sickle cell disease physicians, who very soon will have access to these types of therapies for their patients. And obviously they carry with them a lot of cost, so as we're planning how we're going to provide these treatments, thinking about other ways we can streamline those processes and provide the supportive care that the patients are going to need in order to truly make the experience a valuable one, both from the financial standpoint but also from the viewpoint of the patient.
The other interesting component of hematology and value-based care that I feel very passionate about, and have done a little research in, is the concept of financial toxicity that patients experience when we are administering oral chemotherapy agents. In hematology, our use of oral agents for treatment of malignant diseases is increasing very rapidly, and it's really shifted the responsibility of administering drugs from the clinic and the infusion center to the patient and the caregiver.
It does save costs in that it avoids all of those fees from the facility, the infusion center fees, but what it does then is it places the cost in the hands of the patient as well. I know many of my patients have been faced with fairly large copays to pay for drugs that they need for life-sustaining therapy, simply because their insurance coverage is done in a different way so that they have a lot of costs for orally administered drugs, where they might not have that cost for infusions.
[We’re] really looking into how patients are being affected by this and how we can help mitigate those costs. Obviously, lots of health care systems have systems in place that can support patients through getting grants and assistance from drug companies and things of that nature. I've talked to many patients who say even the process of going through those applications is extremely anxiety provoking and really does impact their quality of life.
From that standpoint, not only are they having to deal with this diagnosis that's overwhelming, but now they're dealing with paperwork and fear that they may lose resources of their own in order to pay for their treatment. I think that's a real area that we need to be thinking about as we create value-based care programs in hematology itself.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More